A new experimental drug called CS18 may help break through cancer drug resistance by disabling several of the defenses tumors use to survive treatment. It strengthened existing therapies, restored dru...

A new experimental drug called CS18 may help break through cancer drug resistance by disabling several of the defenses tumors use to survive treatment. It strengthened existing therapies, restored dru...

HCシリーズの新商品 CS18 抜群のペダルコントロール性能と 耐フェード性能で 街乗りからサーキットまでお楽しみ頂ます😊 是非体感してみてください！ #プロジェクトミュー #CS18 https://t.co/TlhOzwp1Ou

Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts the ability of cancer cells to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 to treat human cancer in the future. "Therapeutic resistance is a main obstacle to achieve effective and durable cancer treatments," said corresponding author Dr. Weei-Chin Lin, professor of medicine – hematology and oncology and of molecular and cellular biology at Baylor. "While some therapies are effective at the beginning, many patients eventually relapse because cancer cells can activate compensatory and convergent biological pathways that allow them to overcome the toxic effects of therapy, promoting survival." In the current study, the researchers' goal was to develop a drug that would target a 'biological switchboard' – topoisomerase IIß-binding protein 1 (TopBP1) – that controls several cancer-driving pathways at once and determine whether this strategy could deliver durable responses and overcome resistance. "Of all the 'biological switches' on TopBP1, switch BRCT7/8 interacts with several key regulators of cancer growth, including MIZ1, a suppressor of cancer driver MYC; mutant p53, which can acquire cancer-promoting functions; and PLK1 and CIP2A, proteins that help cancer cells survive and divide," said Lin,...